{
  "url": "https://openlegislation.uk/misuse-of-drugs-act-1971-modification-order-1996/article-2",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-act-1971-modification-order-1996/article-2.json",
  "legislation": "uksi/1996/1300",
  "legislation_title": "The Misuse of Drugs Act 1971 (Modification) Order 1996",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-act-1971-modification-order-1996",
  "path": "article/2",
  "kind": "article",
  "number": "2",
  "heading": null,
  "text": "(1) Schedule 2 to the Misuse of Drugs Act 1971 (which specifies the drugs which are subject to control under that Act) shall be amended as follows.\n(2) In paragraph 1 of Part III of that Schedule\n(a) the list of substances and products beginning with“Alprazolam”and ending with “Triazolam”shall be designated sub-paragraph (a), and accordingly “(a)”shall be inserted before “Alprazolam”; and\n(b) there shall be added at the end the following sub-paragraphs —\n“(b) Atamestane.\nBolandiol.\nBolasterone.\nBolazine.\nBoldenone.\nBolenol.\nBolmantalate.\nCalusterone.\n4-Chloromethandienone.\nClostebol.\nDrostanolone.\nEnestebol.\nEpitiostanol.\nEthyloestrenol.\nFluoxymesterone.\nFormebolone.\nFurazabol.\nMebolazine.\nMepitiostane.\nMesabolone.\nMestanolone.\nMesterolone.\nMethandienone.\nMethandriol.\nMethenolone.\nMethyltestosterone.\nMetribolone.\nMibolerone.\nNandrolone.\nNorboletone.\nNorclostebol.\nNorethandrolone.\nOvandrotone.\nOxabolone.\nOxandrolone.\nOxymesterone.\nOxymetholone.\nPrasterone.\nPropetandrol.\nQuinbolone.\nRoxibolone.\nSilandrone.\nStanolone.\nStanozolol.\nStenbolone.\nTestosterone.\nThiomesterone.\nTrenbolone.\n(c) any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say,\n(i) by further substitution at position 17 by a methyl or ethyl group;\n(ii) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;\n(iii) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;\n(iv) by fusion of ring A with a heterocyclic system;\n(d) any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above;\n(e) Chorionic Gonadotrophin (HCG).\nClenbuterol.\nNon-human chorionic gonadotrophin.\nSomatotropin.\nSomatrem.\nSomatropin.”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "Schedule 2 has been amended by S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589 and 1995/1966."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/1996/1300/article/2",
    "retrieved_at": "2026-10-29T12:43:47.032566+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}